Literature DB >> 28882457

Characterization of dermal myofibroblast differentiation in pseudoxanthoma elasticum.

Isabel Faust1, Elfi Donhauser2, Bastian Fischer2, Bettina Ibold2, Joachim Kuhn2, Cornelius Knabbe2, Doris Hendig2.   

Abstract

Pseudoxanthoma elasticum (PXE) is a rare hereditary disorder which is caused by ABCC6 (ATP-binding cassette subfamily C member 6) gene mutations. Characteristic hallmarks of PXE are progressive calcification and degradation of the elastic fibers in skin, cardiovascular system and ocular fundus. Since the underlying pathomechanisms of PXE remain unidentified, the aim of this study was to get new insights into PXE pathophysiology by characterizing dermal myofibroblast differentiation. Fibroblasts are the key cells of extracellular matrix (ECM) remodeling and, therefore, participate not only in physiological processes, such as calcification or wound healing, but also in pathologic events, such as fibrotization. We revealed that human dermal PXE fibroblasts possess exaggerated migration capability in wound healing and attenuated myofibroblast contractility in comparison to controls. Subsequent analyses reinforced these observations and indicated a diminished induction of the myofibroblast differentiation markers α-smooth muscle actin and xylosyltransferase-I as well as poor transforming growth factor-β1 responsiveness in PXE fibroblasts. In summary, we describe pathological deviations of dermal myofibroblast differentiation in PXE which might be mediated by aberrant supramolecular ECM organization. These results not only improve our insights into cellular PXE pathophysiology, but might also qualify us to interfere with ECM remodeling in the future.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Connective tissue; Extracellular matrix; Myofibroblast differentiation; Pseudoxanthoma elasticum; Wound healing; Xylosyltransferase

Mesh:

Substances:

Year:  2017        PMID: 28882457     DOI: 10.1016/j.yexcr.2017.09.001

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  The Impact of Inflammatory Stimuli on Xylosyltransferase-I Regulation in Primary Human Dermal Fibroblasts.

Authors:  Thanh-Diep Ly; Christopher Lindenkamp; Eva Kara; Vanessa Schmidt; Anika Kleine; Bastian Fischer; Doris Hendig; Cornelius Knabbe; Isabel Faust-Hinse
Journal:  Biomedicines       Date:  2022-06-19

2.  First Characterization of Human Dermal Fibroblasts Showing a Decreased Xylosyltransferase-I Expression Induced by the CRISPR/Cas9 System.

Authors:  Bastian Fischer; Vanessa Schmidt; Thanh-Diep Ly; Anika Kleine; Cornelius Knabbe; Isabel Faust-Hinse
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

3.  microRNA-29b mediates fibrotic induction of human xylosyltransferase-I in human dermal fibroblasts via the Sp1 pathway.

Authors:  Lara Riedel; Bastian Fischer; Thanh-Diep Ly; Doris Hendig; Joachim Kuhn; Cornelius Knabbe; Isabel Faust
Journal:  Sci Rep       Date:  2018-12-12       Impact factor: 4.379

4.  Evidence of Cardiovascular Calcification and Fibrosis in Pseudoxanthoma Elasticum Mouse Models Subjected to DOCA-Salt Hypertension.

Authors:  Loukman Omarjee; Charlotte Roy; Christophe Leboeuf; Julie Favre; Daniel Henrion; Guillaume Mahe; Georges Leftheriotis; Ludovic Martin; Anne Janin; Gilles Kauffenstein
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

5.  Linking ABCC6 Deficiency in Primary Human Dermal Fibroblasts of PXE Patients to p21-Mediated Premature Cellular Senescence and the Development of a Proinflammatory Secretory Phenotype.

Authors:  Janina Tiemann; Thomas Wagner; Christopher Lindenkamp; Ricarda Plümers; Isabel Faust; Cornelius Knabbe; Doris Hendig
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

6.  Activin A-Mediated Regulation of XT-I in Human Skin Fibroblasts.

Authors:  Thanh-Diep Ly; Ricarda Plümers; Bastian Fischer; Vanessa Schmidt; Doris Hendig; Joachim Kuhn; Cornelius Knabbe; Isabel Faust
Journal:  Biomolecules       Date:  2020-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.